GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hofseth BioCare ASA (OTCPK:HOFBF) » Definitions » Piotroski F-Score

Hofseth BioCare ASA (Hofseth BioCare ASA) Piotroski F-Score : 5 (As of May. 23, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Hofseth BioCare ASA Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Hofseth BioCare ASA has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Hofseth BioCare ASA's Piotroski F-Score or its related term are showing as below:

HOFBF' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 6
Current: 5

During the past 13 years, the highest Piotroski F-Score of Hofseth BioCare ASA was 6. The lowest was 1. And the median was 4.


Hofseth BioCare ASA Piotroski F-Score Historical Data

The historical data trend for Hofseth BioCare ASA's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hofseth BioCare ASA Piotroski F-Score Chart

Hofseth BioCare ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 5.00 2.00 3.00 5.00

Hofseth BioCare ASA Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 6.00 6.00 5.00 5.00

Competitive Comparison of Hofseth BioCare ASA's Piotroski F-Score

For the Biotechnology subindustry, Hofseth BioCare ASA's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hofseth BioCare ASA's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hofseth BioCare ASA's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Hofseth BioCare ASA's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was 0.534 + -2.118 + -4.919 + -2.733 = $-9.24 Mil.
Cash Flow from Operations was 0.293 + 1.028 + -1.09 + -1.834 = $-1.60 Mil.
Revenue was 4.904 + 4.638 + 4.496 + 4.934 = $18.97 Mil.
Gross Profit was 2.395 + 1.48 + -0.19 + 2.357 = $6.04 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(37.149 + 38.064 + 37.482 + 36.98 + 36.818) / 5 = $37.2986 Mil.
Total Assets at the begining of this year (Mar23) was $37.15 Mil.
Long-Term Debt & Capital Lease Obligation was $9.02 Mil.
Total Current Assets was $13.07 Mil.
Total Current Liabilities was $13.17 Mil.
Net Income was -2.912 + -3.405 + -3.869 + -3.592 = $-13.78 Mil.

Revenue was 2.681 + 2.935 + 3.402 + 4.251 = $13.27 Mil.
Gross Profit was 0.861 + 0.558 + 0.605 + 0.329 = $2.35 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(45.044 + 38.868 + 40.913 + 41.602 + 37.149) / 5 = $40.7152 Mil.
Total Assets at the begining of last year (Mar22) was $45.04 Mil.
Long-Term Debt & Capital Lease Obligation was $8.44 Mil.
Total Current Assets was $15.05 Mil.
Total Current Liabilities was $18.01 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Hofseth BioCare ASA's current Net Income (TTM) was -9.24. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Hofseth BioCare ASA's current Cash Flow from Operations (TTM) was -1.60. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=-9.236/37.149
=-0.24862042

ROA (Last Year)=Net Income/Total Assets (Mar22)
=-13.778/45.044
=-0.3058787

Hofseth BioCare ASA's return on assets of this year was -0.24862042. Hofseth BioCare ASA's return on assets of last year was -0.3058787. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Hofseth BioCare ASA's current Net Income (TTM) was -9.24. Hofseth BioCare ASA's current Cash Flow from Operations (TTM) was -1.60. ==> -1.60 > -9.24 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=9.017/37.2986
=0.2417517

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=8.441/40.7152
=0.20731815

Hofseth BioCare ASA's gearing of this year was 0.2417517. Hofseth BioCare ASA's gearing of last year was 0.20731815. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=13.071/13.166
=0.99278444

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=15.045/18.013
=0.83523011

Hofseth BioCare ASA's current ratio of this year was 0.99278444. Hofseth BioCare ASA's current ratio of last year was 0.83523011. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Hofseth BioCare ASA's number of shares in issue this year was 411.549. Hofseth BioCare ASA's number of shares in issue last year was 396.253. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=6.042/18.972
=0.31846932

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2.353/13.269
=0.17733062

Hofseth BioCare ASA's gross margin of this year was 0.31846932. Hofseth BioCare ASA's gross margin of last year was 0.17733062. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=18.972/37.149
=0.51070015

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=13.269/45.044
=0.29457863

Hofseth BioCare ASA's asset turnover of this year was 0.51070015. Hofseth BioCare ASA's asset turnover of last year was 0.29457863. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+0+1+0+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Hofseth BioCare ASA has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Hofseth BioCare ASA  (OTCPK:HOFBF) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Hofseth BioCare ASA Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Hofseth BioCare ASA's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Hofseth BioCare ASA (Hofseth BioCare ASA) Business Description

Traded in Other Exchanges
Address
Kipervikgata 13, Aalesund, NOR, 6003
Hofseth BioCare ASA is a Norway based company engaged in the business of development, manufacturing, marketing and sale of marine ingredients such as oil, calcium and protein products. It is also involved in cooperation, participation, and ownership in the businesses engaged in related activities. The group operates in the business segment of producing salmon oil, soluble protein, calcium, and nonwater soluble protein. The brands under the company are OmeGo, PetGo, ProGo, and CalGo. The firm sells products to various segments of the human nutrition market such as sports nutrition, supplements, and health foods, as well as to the market within nutrition to pet and feed industry. It generates the majority of the revenue from the sale of salmon oil internationally.

Hofseth BioCare ASA (Hofseth BioCare ASA) Headlines